About
Bortezomib is a potent, reversible proteasome inhibitor that disrupts cellular protein homeostasis, leading to apoptosis in cancer cells. It is primarily used in the treatment of multiple myeloma and mantle cell lymphoma. By inhibiting the 26S proteasome, bortezomib prevents the degradation of pro-apoptotic proteins and cell cycle regulatory proteins, thereby inducing cell cycle arrest and programmed cell death in malignant cells.
Its mechanism of action targets a crucial pathway in cancer cell survival and proliferation, making it an effective agent in specific hematological malignancies. Clinical studies have demonstrated its efficacy in improving response rates and overall survival in patients, often used in combination with other therapeutic agents.
Uses
- Treatment of multiple myeloma.
- Management of mantle cell lymphoma.
- Used in patients who have received at least one prior therapy.
- Part of combination therapy regimens.
Directions For Use
Administer intravenously or subcutaneously as directed by a healthcare professional. Dosage and schedule are determined by the patient's condition and treatment protocol.
Benefits
- Targets cancer cells by inhibiting proteasome activity.
- Effective in treating multiple myeloma.
- Beneficial for mantle cell lymphoma patients.
- Can be used in relapsed or refractory settings.
- Improves response rates in specific cancers.
- Offers a targeted approach to cancer therapy.
Side Effects
- Peripheral neuropathy
- Thrombocytopenia
- Neutropenia
- Fatigue
- Nausea
- Diarrhea
- Constipation
- Anemia
- Pyrexia
- Vomiting
- Anorexia
- Rash
Safety Measures
- Alcohol - Avoid or limit alcohol consumption as it may exacerbate certain side effects like liver toxicity or gastrointestinal issues.
- Pregnancy - Not recommended during pregnancy due to potential fetal harm; effective contraception is advised for both male and female patients.
- Breastfeeding - Breastfeeding is not recommended during treatment and for a period after the last dose due to potential harm to the infant.
- Liver - Use with caution in patients with hepatic impairment; dose adjustments may be necessary based on liver function.
- Kidney - Generally safe in patients with renal impairment, but close monitoring is advised; no specific dose adjustment typically required for mild to moderate impairment.
- Lung - Monitor for new or worsening pulmonary symptoms, including interstitial lung disease or acute respiratory distress syndrome.
Disclaimer
MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.
Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.
Our goal is to complement, not replace, the essential doctor-patient relationship.
| Shipping Cost |
|
| Shop Location | Assam, India |
No comments found for this product. Be the first to comment!